The public should be informed of the findings. For example, the likelihood of a patient in a low-income country receiving one or more medicines for secondary prevention of cardiovascular disease is only 19.8 per cent, compared to 54.9 per cent in an upper-middle-income country. The high price of some non-communicable disease medicines, together with the growing burden of non-communicable diseases, could make offering universal health coverage in some countries less effective, less sustainable, or otherwise financially unviable.